Skip to main content

Table 2 Survival outcomes of irinotecan plus temozolomide in Ewing sarcoma

From: Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

First author Survival rates Median OS (Months) Median PFS (Months)
Wagner NA NA 4.7
Anderson NA NA 5.5
Casey NA NA 8.3
Kurucu 1-year OS: 54.2% 1-year PFS: 44.4% 12 (range 6–57) 5.5 (range 2–57)
Palmerini 1-year OS: 55% (95% CI 39–70) 6-month PFS: 49% (95% CI 35–63) NA 3.9 (range 1–29)
Salah 6-month PFS: 39% 14.1 3.8
  1. Abbreviations: OS Overall survival, PFS Progression-free survival, NA Data not available